Form 4: Provectus Biopharmaceuticals CEO Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

CEO Edward Pershing reports the conversion of a convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• On April 19, 2025, Edward Pershing, CEO of Provectus Biopharmaceuticals, reported a transaction involving the conversion of an 8% unsecured convertible promissory note into 9,438 shares of Series D-1 Convertible Preferred Stock.
• The conversion occurred at a price of $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock.
• Following the reported transaction, Pershing beneficially owns 2,072,976 shares of Common Stock and $1,710,000 of Series D-1 Convertible Preferred Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Key Dates

Keywords

Form 4, Beneficial Ownership, Series D-1 Convertible Preferred Stock, Convertible Note, Edward Pershing, Provectus Biopharmaceuticals, PVCT